ArticleCancer medicine2025
STOX1 Isoform A Promotes Proliferation and Progression of Hepatocellular Carcinoma by Dual Mechanisms of Transcriptionally Upregulation of Cyclin B1 and Activation of ROS-Dependent PTEN/AKT1 Signaling.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MTP18 as a prognostic biomarker and therapeutic target in lung adenocarcinoma.Respiratory research · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundDysregulation of transcription factors is one of the most common factors for the pathogenesis of hepatocellular carcinoma (HCC). To the best of our knowledge, no study has yet investigated the clinical significance and functional role of STOX1 in HCC.
methodsReal-time PCR, Western blotting and immunohistochemistry were performed to examine the expression of STOX1-A in HCC specimens. Animal experiment in vivo and functional cell assays in vitro were used to investigate the tumorigenic and proliferative ability of HCC cells. Luciferase and ROS assays were depolyed to investigate the molecular mechanisms underlying the biologic role of STOX1-A in HCC.
resultsIn this study, we report that STOX1 isoform A (STOX1-A) is significantly upregulated in HCC tissues, and elevated STOX1-A levels are associated with poorer overall survival and progression-free survival in HCC patients. Functional assays demonstrated that STOX1-A upregulation promotes, whereas its silencing suppresses, HCC cell proliferation and growth both in vitro and in vivo. Mechanistic investigations revealed a dual mechanism by which STOX1-A drives HCC progression. First, STOX1-A transcriptionally upregulates cyclin B1, promoting cell proliferation. Second, it activates the AKT1 signaling pathway through reactive oxygen species (ROS)-mediated deactivation of PTEN. Furthermore, a positive correlation between STOX1-A expression and the levels of cyclin B1 and phosphorylated AKT1 (p-AKT1 Ser473) was observed in clinical HCC samples.
conclusionOur findings identify a novel dual mechanism by which STOX1-A promotes HCC proliferation and growth, offering potential avenues for the development of anti-tumor therapeutic strategies targeting STOX1-A in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.